134 fibrosis-associated genes

The 134 fibrosis-associated genes refers to a specific transcriptomic signature or diagnostic panel used to assess the progression and severity of fibrotic conditions, particularly Idiopathic Pulmonary Fibrosis (IPF) and Non-Alcoholic Fatty Liver Disease (NAFLD) [1, 5]. In IPF research, this 134-gene signature was identified as a molecular marker capable of distinguishing between patients with stable disease and those at risk for rapid clinical decline [3, 9]. Similarly, in hepatology, a 134-gene set derived from cell-free mRNA has been utilized as a non-invasive classifier to stage liver fibrosis in NAFLD patients [5, 6]. These genes typically involve pathways related to extracellular matrix (ECM) organization, cell adhesion, and immune response [3, 5]. While the signature is not a single therapeutic target, it serves as a vital biomarker for patient stratification and monitoring treatment efficacy in clinical trials [6, 9]. Commercial entities like CCM Biosciences also offer specific NGS panels based on this gene count for diagnostic purposes [2]. The signature reflects the underlying biological activity of myofibroblasts and the dysregulation of wound healing processes [1, 10]. By integrating the expression levels of these 134 genes, clinicians can better predict disease outcomes compared to traditional clinical parameters alone [3, 8]. This approach represents a shift toward precision medicine in the management of chronic fibrotic diseases [1, 6].

Other names

134-gene fibrosis signature134-gene IPF signature134-gene NAFLD fibrosis classifierCCM-7314 panel